|
|
|
|
| LEADER |
00000cam a2200000Mi 4500 |
| 001 |
EBOOKCENTRAL_on1028217468 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
180310s2018 it o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDX
|d IDB
|d MERUC
|d OCLCQ
|d CUY
|d LOA
|d OCLCO
|d ZCU
|d ICG
|d OCLCF
|d COCUF
|d VT2
|d DKC
|d USU
|d OCLCO
|d N$T
|d OCLCO
|d OCLCQ
|d OCLCA
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 019 |
|
|
|a 1028622693
|a 1028647105
|a 1028835526
|a 1028900264
|a 1028935305
|a 1028971394
|a 1029012933
|a 1029207128
|
| 020 |
|
|
|a 8897419747
|
| 020 |
|
|
|a 8897419739
|
| 020 |
|
|
|a 9788897419730
|
| 020 |
|
|
|a 9788897419747
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)1028217468
|z (OCoLC)1028622693
|z (OCoLC)1028647105
|z (OCoLC)1028835526
|z (OCoLC)1028900264
|z (OCoLC)1028935305
|z (OCoLC)1028971394
|z (OCoLC)1029012933
|z (OCoLC)1029207128
|
| 050 |
|
4 |
|a HD9665.5
|b .P437 2018eb
|
| 060 |
|
4 |
|a QV 736.1
|
| 082 |
0 |
4 |
|a 615.10688
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Pharmaceutical market access in developed markets /
|c Güvenç Koçkaya, Albert Wertheimer.
|
| 260 |
|
|
|a Turin :
|b SEEd Medical Publishers,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (325 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Cover; Colophon; Preface; 1. Introduction to the Market Access; 1.1 Origin of the Market Access Term; 1.2 Healthcare Market Access Definition; 1.3 Market Access Key Concepts; 1.4 Cultural Specificities of Market Access; 1.5 Market Access from Payersâ#x80;#x99; Perspective; 1.6 Market Access Agreements; 1.7 Market Access for Orphan Drugs; 1.8 Early Advice; 1.9 Early Access Programs; 1.10 To Know More; 2. Market Access in Germany; 2.1 General Outlook of Healthcare System and Health Policies; 2.2 Pathways of Market Access (Regulation, Pricing, and Reimbursement).
|
| 505 |
8 |
|
|a 2.3 Mapping and Structure of Decision Makers (Reimbursement/HTA)2.4 Organizations/Physician or Patient Organizations; 2.5 Challenges and Catalyzers for Market Access; 2.6 Key Success Factors for Market Access in Germany; 2.7 Look-out for Near Future; 2.8 Acknowledgements; 2.9 References; 3. Market Access in the UK; 3.1 Introduction; 3.2 General Outlook of Healthcare System and Health Policies; 3.3 Pathways of Market Access; 3.4 Mapping and Structure of Decision Makers; 3.5 Challenges and Catalyzers for Market Access; 3.6 Advances in the Near Future; 3.7 Bibliography.
|
| 505 |
8 |
|
|a 4. Market Access in France4.1 General Outlook of Healthcare System; 4.2 Pathways of Market Access (Regulation,  Pricing and Reimbursement); 4.3 Mapping and Structure of Decision Makers; 4.4 Challenges and Catalyzers for Market Access in France; 4.5 Acknowledgements; 4.6 References; 5. Market Access in Italy; 5.1 General Outlook of National Health Service and Health Policies; 5.2 Pathways of Market Access; 5.3 Mapping and Structure of Decision Makers; 5.4 Challenges and Catalyzers for Market Access; 5.5 References; 6. Market Access in Spain.
|
| 505 |
8 |
|
|a 6.1 General Outlook of Healthcare System and Health Policies6.2 Pricing and Reimbursement; 6.3 Mapping and Structure of Decision Makers (Reimbursement/HTA); 6.4 Challenges and Catalyzers for Market Access; 6.5 Innovative Mechanisms for Funding, Purchasing and Paying for Drugs; 6.6 Look-out for Near Future; 6.7 Bibliography; 7. Market Access in Portugal; 7.1 Introduction; 7.2 Healthcare System and Subsystems in Portugal; 7.3 Pathways to Market Access; 7.4 Mapping of Stakeholders; 7.5 Major hurdles; 7.6 References.
|
| 505 |
8 |
|
|a 8. Pharmaceutical Market Access in Denmark, Sweden, and The Netherlands: an Overview8.1 Denmark; 8.2 Sweden; 8.3 The Netherlands; 8.4 References; 9. Market Access in Japan; 9.1 Market Background; 9.2 General Outlook of Healthcare System and Health Policies; 9.3 Structure of Decision Making and Pathways of Market Access; 9.4 Challenges; 9.5 Look-out for Near Future; 9.6 Bibliography; 10. Market Access in Australia; 10.1 Background; 10.2 The Healthcare System; 10.3 Medicare; 10.4 Pathways of Market Access (Regulation, Pricing, and Reimbursement); 10.5 Mapping and Structure of Decision Makers.
|
| 500 |
|
|
|a 10.6 Challenges and Catalyzers for Market Access.
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Drugs
|x Marketing.
|
| 650 |
|
2 |
|a Economics, Pharmaceutical
|
| 650 |
|
2 |
|a Drug Industry
|x economics
|
| 650 |
|
2 |
|a Developed Countries
|
| 650 |
|
6 |
|a Pharmacoéconomie.
|
| 650 |
|
7 |
|a Drugs
|x Marketing
|2 fast
|
| 700 |
1 |
|
|a Koçkaya, Güvenç,
|e editor.
|
| 700 |
1 |
|
|a Wertheimer, Albert,
|e editor.
|
| 758 |
|
|
|i has work:
|a Pharmaceutical market access in developed markets (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCYcWX7JVjgcCPdvdJq98P3
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Koçkaya, Güvenç.
|t Pharmaceutical Market Access in Developed Markets.
|d Turin : SEEd Medical Publishers, ©2018
|z 9788897419730
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5316192
|z Texto completo
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL5316192
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 2207078
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 15212129
|
| 994 |
|
|
|a 92
|b IZTAP
|
